HI-Bio Reports P-II (M-PLACE) and (NewPLACE) Studies Results of Felzartamab to Treat Primary Membranous Nephropathy
Shots:
- The P-II (M-PLACE) study assessed a 9-dose course administered across 9mos. & (NewPLACE) study comprised 2 doses over 2wks. & 5 doses over 2mos. of felzartamab in 31 & 24 patients with aPLA2R+ PMN. The results showed a dose-dependent reduction in pathogenic Ab levels across 2 clinical studies
- In (NewPLACE) study, durable reductions in aPLA2R levels in 9-dose vs 2 & 5-dose regimens. In the final analysis of (M-PLACE), early & substantial reductions in aPLA2R titers as early as 1wk., median reduction of 45% with deep responses (>50% reduction) @6mos. at end-of-treatment
- Improvements in proteinuria & serum albumin levels were seen in (M-PLACE) study highlighting renal recovery, was well tolerated & treatment discontinuation due to TEAE in 7.3%. The company plans to advance felzartamab into late-stage development
Ref: PRNewswire | Image: HI-Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
